爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 100 micrograms/hour - phenylpiperidine derivatives; fentanyl

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 12 micrograms/hour - phenylpiperidine derivatives; fentanyl

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 25 micrograms/hour - phenylpiperidine derivatives; fentanyl

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 50 micrograms/hour - phenylpiperidine derivatives; fentanyl

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 75 micrograms/hour - phenylpiperidine derivatives; fentanyl

美国 - 英文 - NLM (National Library of Medicine)

par pharmaceutical inc. - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 25 ug in 1 h - fentanyl transdermal system is contraindicated in the following patients and situations: clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. observe newborns for symptoms of neonatal opioid withdrawal syndrome, such as poor feeding, diarrhea, irritability, tremor, rigidity, and seizures, and manage accordingly [see warnings precautions (5.4)]. teratogenic effects pregnancy c: there are no adequate and well-controlled studies in pregnant women. fentanyl transdermal system should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. the potential effects of fentanyl on embryo-fetal development were studied in the rat, mouse, and rabbit models. published literature reports that administration of fentanyl (0, 10, 100, or 500 mcg/kg/day) to pregnant female sprague-dawley

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 16.8mg;   - transdermal patch - 100 mcg/h - active: fentanyl 16.8mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 2.1mg;   - transdermal patch - 12 mcg/h - active: fentanyl 2.1mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 4.2mg;   - transdermal patch - 25 mcg/h - active: fentanyl 4.2mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

新西兰 - 英文 - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 6.3mg;   - transdermal patch - 37 mcg/h - active: fentanyl 6.3mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.